A fatal case of cholestatic liver failure probably related to gemcitabine
Single-agent gemcitabine is a good palliative option in advanced non-small-cell lung cancer (NSCLC), because of its activity and rather mild toxicity [1] . We report a NSCLC patient, responding to gemcitabine, but who developed fatal cholestatic liver failure, apparently related to this drug.
In July 1997, a 73-year-old male was admitted for acute pulmonary oedema, due to three vessel coronary heart disease with decreased left ventricular function, as well as a slightly decreased renal function (creatinine 1.5 mg/dl). He had a clinically favourable evolution while on a treatment with beta-1-antagonists, angiotensin-converting-enzyme blockers, nitrates and oral anticoagulants. In February 1998 a coincidental finding of a right-and left-sided coin lesion on chest X-ray was noted. The left lesion proved to be a large cell undifferentiated carcinoma. On PET scan, FDG-uptake compatible with neoplasia was noted in both the left-and right-sided coin lesion, as well as in some mediastinal lymph nodes. No extrathoracic metastases were found. No treatment was instituted at that time, because (bilateral) surgery involved too high a risk. The absence of symptoms and of radiographic tumour evolution justified an awaiting attitude towards chemotherapy. Chest pain, haemoptysis, and radiographic progression developed in February 1999. Gemcitabine (1000 mg/m 2 i.v. on days 1, 8 and 15 of a four-week cycle) was started. The treatment was well tolerated, except for intermittent leukopenia grade 2 and transient slight elevation of the aspartate and alanine transferases. As for efficacy, symptoms gradually diminished, and a partial remission in both lesions was noted after four cycles. In July 1999, the oral anticoagulant was switched temporarily to enoxaprine (a low molecular weight (LMW) heparin) to allow removal of a benign colorectal polyp.
During the sixth cycle, an important elevation of the alkaline phosphatase (532 I.U., upper limit 260), which also had been slightly elevated previously, and of total bilirubin (2.1 mg/dl, upper limit 1) were noted. An abdominal ultrasound showed gall-bladder stones and slight pancreatic lipomatosis, but was unchanged compared to previous ultrasound findings. One week later, a progressive jaundice and cholestatic liver disturbances were present. An abdominal CTestablished slight liver steatosis, no intra-abdominal metastases, known gall-bladder stones, but no arguments for extrahepatic gall-duct obstruction. Serologic tests for viral hepatitis were negative. Despite optimisation of the fluid balance and supportive measures, the liver failure rapidly worsened, and became complicated with coagulation disturbances and renal failure, impeding a liver biopsy. The patient died in multiple organ failure on August 21. At autopsy, the liver architecture was preserved. There was extensive centrilobular parenchymal necrosis. The necrosis was of recent date because there was no collapse or approximation of the portal fields. There were no signs of inflammation, eosinophilia, nuclear debris, mononuclear infiltration, ischemia, or viral inclusion. There was impressive intracellular as well as intra-canalicular cholestasis, without evidence of obstruction. A toxic cause was put forward. Furthermore, a 2 cm large squamous-cell lung cancer was noted in the right upper lobe and a 1 cm large adenocarcinoma in the left upper lobe.
Liver toxicity due to gemcitabine is known, but has repeatedly been described as a slight, transient, asymptomatic, and rapidly reversible elevation of the aspartate and alanine transferases [2, 3] . There is no actual evidence for cumulative hepatotoxicity. The elevation of liver tests rarely leads to termination of treatment [2] [3] [4] , As yet, no overt autopsy-proven cholestatic liver failure has been reported. One report has described a fatal liver event in a phase I dose-finding study of gemcitabine plus 5-FU-folinic acid in patient with pancreatic cancer [5] . Others have reported a patient with fatal venoocclusive disease of the liver [6] .
In this patient, who also had slight renal function impairment, gemcitabine very probably is the causative agent of the severe cholestatic liver disease. Other causes, such as viral hepatitis, liver metastases, choledochus obstruction, were ruled out by appropriate tests. Autopsy confirmed drug-induced cholestatic liver failure. The patient's other medications (beta-1-antagonists, angiotensin-converting-enzyme blockers, nitrates and oral anticoagulants) have not been regularly associated with hepatic side effects, and had been well tolerated since July 1997, which makes a relationship unlikely. The only recently used drug besides gemcitabine, was the LMW heparin. LMW heparin can be associated with slight liver enzyme abnormalities, but this is a rare, and consistently mild phenomenon [7] .
By exclusion, gemcitabine is the probable causative agent in this case, although it can never be completely excluded that a combined effect of gemcitabine together with other medications or factors could be responsible. Gemcitabine should be included in the differential diagnosis of cholestasis during chemotherapy with this agent. 
